OBJECTIVE： To explore the role of clinical pharmacists in therapy for patient with interstitial lung disease （ILD） induced by erlotinib. METHODS： Clinical pharmacists participated in the therapy for ILD in a patient receiving erlotinib target treatment after thoracic vertebra and lumbar radiation， analyzed the cause of ILD and suggested to stop taking imipenem and cilastatin sodium， fluconazol and erlotinib according to lab indexes and patient’s symptom； took prednisone 30 mg，po，qd， for anti-inflammation instead of methylprednisolone； adjusted the dose of prednisone to 40 mg/d， and additionally took Carbocisteine oral solution 10 ml，tid， for improving respiratory symptom； panipenem betamipron 1 g，ivgtt，bid， instead of piperacillin sodium and sulbactam sodium. RESULTS： Physicians adopted the suggestions of clinical pharmacists， and the symptom of anhelation and double pneumonia recovered； discharged medication plan was erlotinib 150 mg，po，qd. CONCLUSIONS： The patient with radiation history easily suffers from ILD when using erlotinib， and should use erlotinib carefully in the clinic. Clinical pharmacists participated in drug therapy and promote safe and rational use of drugs in the clinic.